Dare Bioscience Profit Margin

The latest profit margin for DARE is -804.37% as of June 2026. That compares with -190.68% in the prior-year period — down 321.8% year over year. That is below the Healthcare sector average of 9.48%. Investors often review this figure alongside Dare Bioscience's historical trend and sector peers before judging valuation or financial health.

Over the past year, DARE's profit margin moved from -190.68% to -804.37% — a 321.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Dare Bioscience's valuation or profitability profile.

Against Healthcare companies, DARE currently prints -804.37% for profit margin, while the sector average sits near 9.48%. That is roughly 8584.0% below the sector mean. Large gaps often invite a closer look at Dare Bioscience's growth, margins, and balance sheet.

Profit Margin shows how effectively Dare Bioscience converts resources into returns. At -804.37%, DARE may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -190.68% in the prior-year period — down 321.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting DARE's profit margin (-804.37%), review year-over-year change from -190.68%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.